I personally take any comments from the WHO with a grain of salt but the statement in the attached article regarding remdesivir is interesting. Remdesivir is currently the Standard of Care (SOC) in the U.S. which Brilacidin will be directly compared to in U.S. patients.

https://www.indiatoday.in/coronavirus-outbrea...2020-11-20

“The antiviral drug remdesivir is not suggested for patients admitted to hospital with covid-19, regardless of how severely ill they are, because there is currently no evidence that it improves survival or the need for ventilation, said the WHO guideline.”